| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong [T. L. C., W. Z., S. Y. L., S. T. Y.], and Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, CB10 1SA, United Kingdom
Colorectal cancer is believed to progress through an adenoma–carcinoma sequence. However, recent evidence increasingly supports the existence of an alternative route for colorectal carcinogenesis through serrated polyps, a group that encompasses a morphological spectrum, including hyperplastic polyp (HP), admixed hyperplastic polyp/adenoma (HP/AD), and serrated adenoma (SA; the latter two manifest epithelial dysplasia). We have studied a large series of serrated polyps for BRAF and KRAS mutations. BRAF mutations were detected in 18 of 50 (36%) HPs, 2 of 10 (20%) HP/ADs, and 9 of 9 (100%) SAs. Twenty-six of 29 mutations caused amino acid substitutions at valine 599, the known hotspot. KRAS mutations were detected in 9 of 50 (18%) HPs, 6 of 10 (60%) HP/ADs, and 0 of 9 (0%) SAs. BRAF and KRAS mutations are mutually exclusive (P = 0.001). The associations of BRAF mutations with SAs (P < 0.001) and KRAS mutations with HP/ADs (P = 0.005) are statistically significant. A majority (90%) of the serrated polyps showing dysplasia had mutations in either BRAF or KRAS, significantly different from those without dysplasia (54%; P = 0.014). Our data highlight the important role of activation of the RAS-RAF-mitogen-activated protein/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase-mitogen-activated protein kinase pathway in the initiation and progression of serrated neoplasms. Acquisition of a BRAF mutation appears to be associated with the progression of HP to SA, whereas progression to HP/AD is predominantly associated with acquisition of a KRAS mutation. The high incidence of BRAF mutations in HPs and SAs is consistent with the notion that the group of colorectal cancers carrying BRAF mutations may harbor most that have progressed through the HP-SA-carcinoma pathway.
This article has been cited by other articles:
|
|
 |
|
  E Denayer, T. de Ravel, and E Legius Clinical and molecular aspects of RAS related disorders J. Med. Genet., November 1, 2008; 45(11): 695 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J J Y Sung, J Y W Lau, G P Young, Y Sano, H M Chiu, J S Byeon, K G Yeoh, K L Goh, J Sollano, R Rerknimitr, et al. Asia Pacific consensus recommendations for colorectal cancer screening Gut, August 1, 2008; 57(8): 1166 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Suehiro, C. W. Wong, L. R. Chirieac, Y. Kondo, L. Shen, C. R. Webb, Y. W. Chan, A. S.Y. Chan, T. L. Chan, T.-T. Wu, et al. Epigenetic-Genetic Interactions in the APC/WNT, RAS/RAF, and P53 Pathways in Colorectal Carcinoma Clin. Cancer Res., May 1, 2008; 14(9): 2560 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Crawford, D. Belajic, J. Wei, J. P. Riley, P. J. Dunford, S. Bembenek, A. Fourie, J. P. Edwards, L. Karlsson, A. Brunmark, et al. A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker Mol. Cancer Ther., March 1, 2008; 7(3): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Uronis, H. H. Herfarth, T. C. Rubinas, A. C. Bissahoyo, K. Hanlon, and D. W. Threadgill Flat Colorectal Cancers Are Genetically Determined and Progress to Invasion without Going through a Polypoid Stage Cancer Res., December 15, 2007; 67(24): 11594 - 11600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Young and J. R. Jass The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1778 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Sapio, D. Posca, G. Troncone, G. Pettinato, L. Palombini, G. Rossi, G. Fenzi, and M. Vitale Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA) Eur. J. Endocrinol., February 1, 2006; 154(2): 341 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Haigis, J. Sage, J. Glickman, S. Shafer, and T. Jacks The Related Retinoblastoma (pRb) and p130 Proteins Cooperate to Regulate Homeostasis in the Intestinal Epithelium J. Biol. Chem., January 6, 2006; 281(1): 638 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sweet, J. Willis, X.-P. Zhou, C. Gallione, T. Sawada, P. Alhopuro, S. K. Khoo, A. Patocs, C. Martin, S. Bridgeman, et al. Molecular Classification of Patients With Unexplained Hamartomatous and Hyperplastic Polyposis JAMA, November 16, 2005; 294(19): 2465 - 2473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-M. Shih and R. J. Kurman Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges Clin. Cancer Res., October 15, 2005; 11(20): 7273 - 7279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C W Wong, Y S Fan, T L Chan, A S W Chan, L C Ho, T K F Ma, the Cancer Genome Project, S T Yuen, and S Y Leung BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs J. Clin. Pathol., June 1, 2005; 58(6): 640 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Beach, A. O.-O. Chan, T.-T. Wu, J. A. White, J. S. Morris, S. Lunagomez, R. R. Broaddus, J.-P. J. Issa, S. R. Hamilton, and A. Rashid BRAF Mutations in Aberrant Crypt Foci and Hyperplastic Polyposis Am. J. Pathol., April 1, 2005; 166(4): 1069 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A J M Watson Apoptosis and colorectal cancer Gut, November 1, 2004; 53(11): 1701 - 1709. [Full Text] [PDF]
|
|
|
|
|
|
C.-L. Ho, R. J. Kurman, R. Dehari, T.-L. Wang, and I.-M. Shih Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors Cancer Res., October 1, 2004; 64(19): 6915 - 6918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Kambara, L A Simms, V L J Whitehall, K J Spring, C V A Wynter, M D Walsh, M A Barker, S Arnold, A McGivern, N Matsubara, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum Gut, August 1, 2004; 53(8): 1137 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Higuchi and J R Jass My approach to serrated polyps of the colorectum J. Clin. Pathol., July 1, 2004; 57(7): 682 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ikenoue, Y. Hikiba, F. Kanai, J. Aragaki, Y. Tanaka, J. Imamura, T. Imamura, M. Ohta, H. Ijichi, K. Tateishi, et al. Different Effects of Point Mutations within the B-Raf Glycine-Rich Loop in Colorectal Tumors on Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase and Nuclear Factor {kappa}B Pathway and Cellular Transformation Cancer Res., May 15, 2004; 64(10): 3428 - 3435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Konishi, T. Yamochi, R. Makino, K. Kaneko, T. Yamamoto, H. Nozawa, A. Katagiri, H. Ito, K. Nakayama, H. Ota, et al. Molecular Differences between Sporadic Serrated and Conventional Colorectal Adenomas Clin. Cancer Res., May 1, 2004; 10(9): 3082 - 3090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C V A Wynter, M D Walsh, T Higuchi, B A Leggett, J Young, and J R Jass Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer Gut, April 1, 2004; 53(4): 573 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Xing, Y. Cohen, E. Mambo, G. Tallini, R. Udelsman, P. W. Ladenson, and D. Sidransky Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis Cancer Res., March 1, 2004; 64(5): 1664 - 1668. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
